Biopiracy? Are pharmaceutical companies stealing the genetic information in the developing world’s flora and fauna?

Low-income countries – where much of the world’s biodiversity remains – hope it could funnel billions into conserving the rainforests, lakes and oceans where such organisms live.

Examples of what is at stake grow every year. The discovery of the heat-resistant Thermus aquaticus bacterium in the geysers of Yellowstone national park in 1966 became a crucial ingredient for rapidly copying DNA in the polymerase chain reaction process, used in Covid-19 tests. Plastic-eating bacteria could provide a breakthrough for recycling.

Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other ‘disruptive’ innovations. Subscribe to our newsletter.

The debate over the ethical use of data from nature – and who should profit – is fierce. The natural world has long been the basis of commercial discoveries, particularly in medicine.

In 2019, the Wellcome Sanger Institute, a leading genetics lab in Cambridgeshire, was accused of misusing African DNA and told to hand back samples it had collected from Indigenous communities in southern Africa after a whistleblower alleged the DNA information was being used to develop a medical research tool that could have been commercialised.

In the early 2000s, the Kenya Wildlife Service threatened legal action against Genencor and Procter & Gamble, alleging that enzymes obtained from a soda lake in the country were being used in a detergent.

This is an excerpt. Read the original post here